Moreover, Giantin gene mutations and pathogenic changes in Giantin levels have been reported in various diseases, including sickle cell disease (Alsultan et al., 2018; Amlie-Lefond et al., 2018), bipolar disorder (Kerner et al., 2013), hepatocellular carcinoma (Choi et al., 2017), leukemia (Troadec et al., 2017), pulmonary disease (Raparelli et al., 2018), and post-alcohol recovery (Casey et al., 2018). Here, GOLGB1 is linked to bipolar disorder.